CAR-T cell therapy for multiple myeloma: a practical toolkit for treatment in Brazil

Hungria, Vânia; Piérola, Ana Alfonso; Filho, Jayr Schmidt; Crusoé, Edvan; Filho, Roberto Jose Pessoa de Magalhaes; Maiolino, Ângelo; Rodríguez‐Otero, Paula

doi:10.1016/j.htct.2022.08.002

Cited by 5 publications

(1 citation statement)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…India recently initiated a phase III clinical trial at a Mumbai Hospital ( 35 , 36 ) with a strategy to manufacture CAR-T cells on-site, aiming to reduce ten-fold costs compared to commercial products. Brazil has authorized more than 18 clinical trials with Advanced Therapy Products since 2018, and in July 2022, the first CAR-T cell therapy clinical trial was authorized ( 37 , 38 ). Initiatives for global access to CAR-T cell therapies are ongoing in different parts of the world ( 39 ).…”

Section: Understanding the Designs And Clinical Concepts Of Car-t Cellsmentioning

confidence: 99%

Childhood leukemias in Mexico: towards implementing CAR-T cell therapy programs

Bustamante-Ogando,

Hernández-López,

Galván-Díaz

et al. 2024

Front. Oncol.

View full text Add to dashboard Cite

Leukemias are the most common type of pediatric cancer around the world. Prognosis has improved during the last decades, and many patients are cured with conventional treatment as chemotherapy; however, many patients still present with a refractory disease requiring additional treatments, including hematopoietic stem cell transplantation. Immunotherapy with monoclonal antibodies or cellular therapy is a promising strategy for treating refractory or relapsed hematological malignancies. Particularly, CAR-T cells have shown clinical efficacy in clinical trials, and different products are now commercially approved by regulatory agencies in the USA and Europe. Many challenges still need to be solved to improve and optimize the potential of these therapies worldwide. Global access to cell therapy is a significant concern, and different strategies are being explored in the middle- and low-income countries. In Mexico, leukemias represent around 50% of total cancer diagnosed in pediatric patients, and the rate of relapsed or refractory disease is higher than reported in other countries, a multi-factorial problem. Although significant progress has been made during the last decades in leukemia diagnosis and treatment, making new therapies available to Mexican patients is a priority, and cell and gene therapies are on the horizon. Efforts are ongoing to make CAR-T cell therapy accessible for patients in Mexico. This article summarizes a general landscape of childhood leukemias in Mexico, and we give a perspective about the current strategies, advances, and challenges ahead to make gene and cell therapies for leukemia clinically available.

show abstract

Section: Understanding the Designs And Clinical Concepts Of Car-t Cellsmentioning

confidence: 99%

Childhood leukemias in Mexico: towards implementing CAR-T cell therapy programs

Bustamante-Ogando,

Hernández-López,

Galván-Díaz

et al. 2024

Front. Oncol.

View full text Add to dashboard Cite

show abstract

Access to CAR T-cell therapy: Focus on diversity, equity and inclusion

Odstrcil,

Lee,

Sobieski

et al. 2024

Blood Reviews

View full text Add to dashboard Cite

The translational gap for gene therapies in low- and middle-income countries

Doxzen,

Adair,

Fonseca Bazzo

et al. 2024

Sci. Transl. Med.

View full text Add to dashboard Cite

Gene therapies are designed to address the root cause of disease. As scientific understanding of disease prevention, diagnosis, and treatment improves in tandem with technological innovation, gene therapies have the potential to become safe and effective treatment options for a wide range of genetic and nongenetic diseases. However, as the medical scope of gene therapies expands, consideration must be given to those who will benefit and what proactive steps must be taken to widen development and access potential, particularly in regions carrying a high disease burden.

show abstract

CAR-T cell therapy for multiple myeloma: a practical toolkit for treatment in Brazil

Cited by 5 publications

References 25 publications

Childhood leukemias in Mexico: towards implementing CAR-T cell therapy programs

Childhood leukemias in Mexico: towards implementing CAR-T cell therapy programs

Access to CAR T-cell therapy: Focus on diversity, equity and inclusion

The translational gap for gene therapies in low- and middle-income countries

Contact Info

Product

Resources

About